Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and is closely linked with autism. The genetic basis of FXS is an expansion of CGG repeats in the 5′-untranslated region of the FMR1 gene on the X chromosome leading to the loss of expression of the fragile X mental retardation protein (FMRP). The cause of FXS has been known for over 20 years, yet the full molecular and cellular consequences of this mutation remain unclear. Although mouse and fly models have provided significant understanding of this disorder and its effects on the central nervous system, insight from human studies is limited. We have created human induced pluripotent stem cell (iPSC) lines from fibroblasts obtained from individuals with FXS to enable in vitro modeling of the human disease. Three young boys with FXS who came from a well-characterized cohort representative of the range of affectedness typical for the syndrome were recruited to aid in linking cellular and behavioral phenotypes. The FMR1 mutation is preserved during the reprogramming of patient fibroblasts to iPSCs. Mosaicism of the CGG repeat length in one of the patient's fibroblasts allowed for the generation of isogenic lines with differing CGG repeat lengths from the same patient. FXS forebrain neurons were differentiated from these iPSCs and display defective neurite initiation and extension. These cells provide a well-characterized resource to examine potential neuronal deficits caused by FXS as well as the function of FMRP in human neurons.
Get full access to this article
View all access options for this article.
References
1.
HagermanRJ and HagermanPJ. (2002). Fragile X Syndrome. Johns Hopkins University Press, Baltimore MD.
2.
HagermanRJ, OnoMY and HagermanPJ. (2005). Recent advances in fragile X: a model for autism and neurodegeneration. Curr Opin Psychiatry, 18:490–496.
3.
CoffeeB, ZhangF, WarrenST and ReinesD. (1999). Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet, 22:98–101.
4.
VerkerkAJ, PierettiM, SutcliffeJS, FuYH, KuhlDP, PizzutiA, ReinerO, RichardsS, VictoriaMF and ZhangFP. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell, 65:905–914.
5.
PierettiM, ZhangFP, FuYH, WarrenST, OostraBA, CaskeyCT and NelsonDL. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell, 66:817–822.
6.
VerheijC, BakkerCE, de GraaffE, KeulemansJ, WillemsenR, VerkerkAJ, GaljaardH, ReuserAJ, HoogeveenAT and OostraBA. (1993). Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature, 363:722–724.
7.
CoffeeB, ZhangF, CemanS, WarrenST and ReinesD. (2002). Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome. Am J Hum Genet, 71:923–932.
8.
DevysD, LutzY, RouyerN, BellocqJP and MandelJL. (1993). The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet, 4:335–340.
9.
EberhartDE, MalterHE, FengY and WarrenST. (1996). The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet, 5:1083–1091.
10.
FengY, GutekunstCA, EberhartDE, YiH, WarrenST and HerschSM. (1997). Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci, 17:1539–1547.
11.
HindsHL, AshleyCT, SutcliffeJS, NelsonDL, WarrenST, HousmanDE and SchallingM. (1993). Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet, 3:36–43.
12.
SidorovMS, AuerbachBD and BearMF. (2013). Fragile X mental retardation protein and synaptic plasticity. Mol brain, 6:15
13.
AshleyCTJr., WilkinsonKD, ReinesD and WarrenST. (1993). FMR1 protein: conserved RNP family domains and selective RNA binding. Science, 262:563–566.
14.
BrownV, JinP, CemanS, DarnellJC, O'DonnellWT, TenenbaumSA, JinX, FengY, WilkinsonKD, et al. (2001). Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell, 107:477–487.
15.
MiyashiroKY, Beckel-MitchenerA, PurkTP, BeckerKG, BarretT, LiuL, CarbonettoS, WeilerIJ, GreenoughWT and EberwineJ. (2003). RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron, 37:417–431.
16.
IossifovI, RonemusM, LevyD, WangZ, HakkerI, RosenbaumJ, YamromB, LeeYH, NarzisiG, et al. (2012). De novo gene disruptions in children on the autistic spectrum. Neuron, 74:285–299.
17.
DarnellJ. (2011). Defects in translational regulation contributing to human cognitive and behavioral disease. Curr Opin Genet Dev, 21:465–473.
18.
BolducFV, BellK, CoxH, BroadieKS and TullyT. (2008). Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. Nat Neurosci, 11:1143–1145.
19.
DockendorffTC, SuHS, McBrideSM, YangZ, ChoiCH, SiwickiKK, SehgalA and JongensTA. (2002). Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron, 34:973–984.
20.
GrossmanAW, ElisseouNM, McKinneyBC and GreenoughWT. (2006). Hippocampal pyramidal cells in adult Fmr1 knockout mice exhibit an immature-appearing profile of dendritic spines. Brain Res, 1084:158–164.
21.
MoralesJ, HiesingerPR, SchroederAJ, KumeK, VerstrekenP, JacksonFR, NelsonDL and HassanBA. (2002). Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron, 34:961–972.
22.
PanL, ZhangYQ, WoodruffE and BroadieK. (2004). The Drosophila fragile X gene negatively regulates neuronal elaboration and synaptic differentiation. Curr Biol, 14:1863–1870.
23.
TuckerB, RichardsRI and LardelliM. (2006). Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum Mol Genet, 15:3446–3458.
24.
ZhangYQ, BaileyAM, MatthiesHJ, RendenRB, SmithMA, SpeeseSD, RubinGM and BroadieK. (2001). Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell, 107:591–603.
25.
BakkerCE and OostraBA. (2003). Understanding fragile X syndrome: insights from animal models. Cytogenet Genome Res, 100:111–123.
26.
BrouwerJR, MientjesEJ, BakkerCE, NieuwenhuizenIM, SeverijnenLA, Van der LindeHC, NelsonDL, OostraBA and WillemsenR. (2007). Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated fragile X full mutation. Exp Cell Res, 313:244–253.
27.
UrbachA, Bar-NurO, DaleyGQ and BenvenistyN. (2010). Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell, 6:407–411.
28.
EigesR, UrbachA, MalcovM, FrumkinT, SchwartzT, AmitA, YaronY, EdenA, YanukaO, BenvenistyN and Ben YosefD. (2007). Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell, 1:568–577.
29.
SheridanSD, TheriaultKM, ReisSA, ZhouF, MadisonJM, DaheronL, LoringJF and HaggartySJ. (2011). Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One, 6:e26203
30.
TakahashiK, TanabeK, OhnukiM, NaritaM, IchisakaT, TomodaK and YamanakaS. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131:861–872.
31.
YuJ, VodyanikMA, Smuga-OttoK, Antosiewicz-BourgetJ, FraneJL, TianS, NieJ, JonsdottirGA, RuottiV, et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318:1917–1920.
HuBY and ZhangSC. (2010). Directed differentiation of neural-stem cells and subtype-specific neurons from hESCs. Methods Mol Biol, 636:123–137.
34.
HuBY, WeickJP, YuJ, MaLX, ZhangXQ, ThomsonJA and ZhangSC. (2010). Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A, 107:4335–4340.
35.
ChambersSM, FasanoCA, PapapetrouEP, TomishimaM, SadelainM and StuderL. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol, 27:275–280.
36.
SchmittgenTD and LivakKJ. (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc, 3:1101–1108.
37.
SeltzerMM, BakerMW, HongJ, MaennerM, GreenbergJ and MandelD. (2012). Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet, 159B:589–597.
38.
DentEW and MeiriKF. (1992). GAP-43 phosphorylation is dynamically regulated in individual growth cones. J Neurobiol, 23:1037–1053.
39.
MaennerMJ, BakerMW, BromanKW, TianJ, BarnesJK, AtkinsA, McPhersonE, HongJ, BrilliantMH and MailickMR. (2013). FMR1 CGG expansions: prevalence and sex ratios. Am J Med Genet B Neuropsychiatr Genet, 162B:466–473.
40.
NolinSL, GlicksmanA, HouckGEJr., BrownWT and DobkinCS. (1994). Mosaicism in fragile X affected males. Am J Med Genet, 51:509–512.
41.
TassoneF, BeilinaA, CarosiC, AlbertosiS, BagniC, LiL, GloverK, BentleyD and HagermanPJ. (2007). Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA, 13:555–562.
42.
AbitbolM, MeniniC, DelezoideAL, RhynerT, VekemansM and MalletJ. (1993). Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain. Nat Genet, 4:147–153.
43.
LiuH and ZhangSC. (2011). Specification of neuronal and glial subtypes from human pluripotent stem cells. Cell Mol Life Sci, 68:3995–4008.
44.
AntarLN, LiC, ZhangH, CarrollRC and BassellGJ. (2006). Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol Cell Neurosci, 32:37–48.
45.
BassellGJ and WarrenST. (2008). Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron, 60:201–214.
46.
DictenbergJB, SwangerSA, AntarLN, SingerRH and BassellGJ. (2008). A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev Cell, 14:926–939.
47.
BhattacharyyaA, McMillanE, WallaceK, TubonTCJr., CapowskiEE and SvendsenCN. (2008). Normal neurogenesis but abnormal gene expression in human fragile X cortical progenitor cells. Stem Cells Dev, 17:107–117.
48.
CastrenM, TervonenT, KarkkainenV, HeinonenS, CastrenE, LarssonK, BakkerCE, OostraBA and AkermanK. (2005). Altered differentiation of neural stem cells in fragile X syndrome. Proc Natl Acad Sci U S A, 102:17834–17839.
49.
TeliasM, SegalM and Ben-YosefD. (2013). Neural differentiation of fragile X human embryonic stem cells reveals abnormal patterns of development despite successful neurogenesis. Dev Biol, 374:32–45.
Martins-TaylorK, NislerBS, TaapkenSM, ComptonT, CrandallL, MontgomeryKD, LalandeM and XuRH. (2011). Recurrent copy number variations in human induced pluripotent stem cells. Nat Biotechnol, 29:488–491.
52.
GoreA, LiZ, FungHL, YoungJE, AgarwalS, Antosiewicz-BourgetJ, CantoI, GiorgettiA, IsraelMA, et al. (2011). Somatic coding mutations in human induced pluripotent stem cells. Nature, 471:63–67.
53.
WangT, WarrenST and JinP. (2013). Toward pluripotency by reprogramming: mechanisms and application. Protein Cell, 4:820–832.
54.
McConnellMJ, LindbergMR, BrennandKJ, PiperJC, VoetT, Cowing-ZitronC, ShumilinaS, LaskenRS, VermeeschJR, HallIM and GageFH. (2013). Mosaic copy number variation in human neurons. Science, 342:632–637.
55.
KunstCB, LeeflangEP, IberJC, ArnheimN and WarrenST. (1997). The effect of FMR1 CGG repeat interruptions on mutation frequency as measured by sperm typing. J Med Genet, 34:627–631.
56.
JinP and WarrenST. (2000). Understanding the molecular basis of fragile X syndrome. Hum Mol Genet, 9:901–908.
57.
LoeschDZ, HugginsR, HayDA, GedeonAK, MulleyJC and SutherlandGR. (1993). Genotype-phenotype relationships in fragile X syndrome: a family study. Am J Hum Genet, 53:1064–1073.
58.
LoeschDZ, HugginsRM and HagermanRJ. (2004). Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev, 10:31–41.
59.
HagermanRJ, HullCE, SafandaJF, CarpenterI, StaleyLW, O'ConnorRA, SeydelC, MazzoccoMM, SnowK, ThibodeauSN, et al. (1994). High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet, 51:298–308.
60.
LoeschDZ, SherwellS, KinsellaG, TassoneF, TaylorA, AmorD, SungS and EvansA. (2012). Fragile X-associated tremor/ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene. Clin Genet, 82:88–92.
61.
JohnsonMA, WeickJP, PearceRA and ZhangSC. (2007). Functional neural development from human embryonic stem cells: accelerated synaptic activity via astrocyte coculture. J Neurosci, 27:3069–3077.
62.
PankratzMT, LiXJ, LavauteTM, LyonsEA, ChenX and ZhangSC. (2007). Directed neural differentiation of human embryonic stem cells via an obligated primitive anterior stage. Stem Cells, 25:1511–1520.
63.
ShiY, KirwanP and LiveseyFJ. (2012). Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc, 7:1836–1846.
64.
WisniewskiKE, SeganSM, MiezejeskiCM, SersenEA and RudelliRD. (1991). The Fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. Am J Med Genet, 38:476–480.
65.
IrwinSA, PatelB, IdupulapatiM, HarrisJB, CrisostomoRA, LarsenBP, KooyF, WillemsPJ, CrasP, et al. (2001). Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet, 98:161–167.
66.
HintonVJ, BrownWT, WisniewskiK and RudelliRD. (1991). Analysis of neocortex in three males with the fragile X syndrome. Am J Med Genet, 41:289–294.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
